M&A Drives 3SBio’s Biosimilars Expansion Potential
This article was originally published in PharmAsia News
3SBio has made its second acquisition for expanded product portfolio in biosimilars and antibodies since listing in Hong Kong. The majority stake buyout deal landed on the Chinese biosimilar and antibody developer Shanghai CP Guojian Pharmaceutical. Through the integration, two companies could develop oversea markets together.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.